Cardiovascular Health

DHA, Not EPA, Is Big Fish of Omega-3s

By August West | Contributing Writer - Vol. 1, No. 1. , 2000

Many commonly used pharmaceuticals deplete key nutrients, leading to a progressive decline in nutrition and health status. This chart, the first of a series, identifies nutritional depletions associated with diuretics, cholesterol lowering drugs and other cardiovascular medicines, and outlines simple nutritional interventions to correct the problems.

The Content you are trying to see is available only for members of our site. If you already have a Membership you need to log in to see it. Please follow this link if you want to register.

CoQ10 and CHF: Start Early to Optimize Myocardial Function

By Dana Trevas | Contributing Writer

LAS VEGAS—Co-enzyme Q10 supplementation can improve heart function and survival in patients with congestive heart failure, provided it is given early on in the course of disease, said Stephen Sinatra, MD, at the American College of Nutrition’s annual meeting.

The Content you are trying to see is available only for members of our site. If you already have a Membership you need to log in to see it. Please follow this link if you want to register.

How High Is Too High? Elevated Homocysteine Raises Stroke Specter

By Peggy Peck | Contributing Writer - Vol. 2, No. 2. , 2001

Epidemiologically, elevated homocysteine levels are correlated with increased risk of stroke. But on an individual basis, it is difficult to know when someone’s homocysteine measurement is signaling an increased likelihood of stroke.

 

The Content you are trying to see is available only for members of our site. If you already have a Membership you need to log in to see it. Please follow this link if you want to register.

Helping Patients Take the Path Out of Cardiovascular Pathology

By Erik L. Goldman | Editor in Chief - Vol. 4, No. 2. , 2003

SALT LAKE CITY—When talking to your patients about heart disease, offer them the choice between a Path or a Pathology, and help them identify their own obstacles to a healthier lifestyle, said S. A. Decker Weiss, NMD, at the annual meeting of the American Association of Naturopathic Physicians.

The Content you are trying to see is available only for members of our site. If you already have a Membership you need to log in to see it. Please follow this link if you want to register.

CV Risk Reduction Requires Much More than Statins

By Erik L. Goldman | Editor in Chief

ANAHEIM, CA—Statins will only go so far in reducing the incidence of cardiovascular events, said H. Robert Superko, MD, at Nutracon, an annual conference on advances in nutraceutical product development.

The Content you are trying to see is available only for members of our site. If you already have a Membership you need to log in to see it. Please follow this link if you want to register.

Extended-Release Niacin Boosts Lipid-Lowering Power of Statin

By Erik L. Goldman | Editor in Chief - Vol. 3, No. 2. , 2002

Niacin is every effective in reducing LDL and elevating HDL or “good” cholesterol. But it is under-used in part because many people taking standard forms of niacin experience intense flushing. Extended release forms of niacin are now available that eliminate this problem. A statin-niacin combination called Advicor is “the ideal drug combination” for reducing heart disease risk, says cardiologist William Insull, MD.

“Top Ten” Natural Approaches for Managing Coronary Artery Disease

By Erik L. Goldman | Editor in Chief

PHILADELPHIA—Holistic medicine is often considered more preventive than therapeutic, especially when it comes to cardiovascular disease. But even patients with advanced heart disease can benefit greatly from multimodal natural therapeutics.

The Content you are trying to see is available only for members of our site. If you already have a Membership you need to log in to see it. Please follow this link if you want to register.

NIH-Sponsored Chelation Trial Seeks Study Sites for Heart Disease Patients

By Staff Writer - Vol. 9, No. 1. , 2008

Chelation therapy to prevent heart attacks has never been accepted by mainstream cardiologists, but it is popular none the less, and increasingly so in the wake of trials questioning the value of drug-eluting stents. The Trial to Assess Chelation Therapy (TACT), a $30 million NIH-sponsored study, will hopefully provide definitive answers on whether chelation has a rightful place in heart disease prevention.

The Content you are trying to see is available only for members of our site. If you already have a Membership you need to log in to see it. Please follow this link if you want to register.